(CVRX) CVRx - Ratings and Ratios
Neuromodulation Device
CVRX EPS (Earnings per Share)
CVRX Revenue
Description: CVRX CVRx October 29, 2025
CVRx, Inc. (NASDAQ: CVRX) is a commercial-stage medical-device firm that designs, manufactures, and markets neuromodulation therapies for cardiovascular disease, primarily in the United States and Germany. Its flagship product, Barostim, delivers calibrated electrical pulses to baroreceptors to improve symptoms and functional capacity in patients with chronic heart-failure with reduced ejection fraction (HFrEF). The company distributes its devices through a hybrid model of a direct sales force, third-party agents, and independent distributors, and has been operating since its 2000 incorporation in Minneapolis, Minnesota.
Recent public filings (FY 2023) show that CVRx generated roughly $30 million in revenue, with a year-over-year growth rate of about 12 % driven by expanding adoption of Barostim in U.S. heart-failure clinics. The firm posted a net loss of $45 million, reflecting high R&D spend (≈ $25 million) and ongoing commercial rollout costs. Key sector drivers include the aging U.S. population (the prevalence of HFrEF is expected to rise 15 % by 2030) and favorable reimbursement trends under Medicare’s Chronic Heart Failure Bundle, which have begun to improve payer acceptance of neuromodulation therapies. Competitive pressure comes from implantable monitoring solutions such as Abbott’s CardioMEMS, underscoring the importance of demonstrating cost-effectiveness and clinical outcome data in future trials.
For a deeper, data-driven look at ValueRay’s valuation and how it compares to peers, you may want to review the latest analyst commentary and the company’s most recent 10-Q filing.
CVRX Stock Overview
| Market Cap in USD | 271m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2021-06-30 |
CVRX Stock Ratings
| Growth Rating | -39.4% |
| Fundamental | 31.6% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -46.6% |
| Analyst Rating | 4.57 of 5 |
CVRX Dividends
Currently no dividends paidCVRX Growth Ratios
| Growth Correlation 3m | 80.9% |
| Growth Correlation 12m | -61.7% |
| Growth Correlation 5y | -15.4% |
| CAGR 5y | -6.41% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.07 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.13 |
| Sharpe Ratio 12m | -0.05 |
| Alpha | -50.56 |
| Beta | 1.221 |
| Volatility | 95.93% |
| Current Volume | 227.6k |
| Average Volume 20d | 217.5k |
| Stop Loss | 9.1 (-7%) |
| Signal | -0.79 |
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income (-52.3m TTM) > 0 and > 6% of Revenue (6% = 3.28m TTM) |
| FCFTA -0.33 (>2.0%) and ΔFCFTA 6.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 194.8% (prev 186.7%; Δ 8.12pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.33 (>3.0%) and CFO -39.1m > Net Income -52.3m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 11.99 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (26.1m) change vs 12m ago 20.54% (target <= -2.0% for YES) |
| Gross Margin 84.04% (prev 83.79%; Δ 0.26pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 50.71% (prev 46.25%; Δ 4.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -8.67 (EBITDA TTM -46.2m / Interest Expense TTM 5.41m) >= 6 (WARN >= 3) |
Altman Z'' -22.15
| (A) 0.89 = (Total Current Assets 116.1m - Total Current Liabilities 9.69m) / Total Assets 119.6m |
| (B) -4.73 = Retained Earnings (Balance) -565.8m / Total Assets 119.6m |
| warn (B) unusual magnitude: -4.73 — check mapping/units |
| (C) -0.43 = EBIT TTM -46.9m / Avg Total Assets 107.8m |
| (D) -9.18 = Book Value of Equity -565.8m / Total Liabilities 61.6m |
| Total Rating: -22.15 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 31.57
| 1. Piotroski 1.50pt = -3.50 |
| 2. FCF Yield -17.41% = -5.0 |
| 3. FCF Margin -72.14% = -7.50 |
| 4. Debt/Equity 0.87 = 2.13 |
| 5. Debt/Ebitda 0.96 = 1.82 |
| 6. ROIC - WACC (= -50.00)% = -12.50 |
| 7. RoE -79.31% = -2.50 |
| 8. Rev. Trend 92.65% = 6.95 |
| 9. EPS Trend 33.32% = 1.67 |
What is the price of CVRX shares?
Over the past week, the price has changed by -9.44%, over one month by +12.14%, over three months by +43.86% and over the past year by -36.51%.
Is CVRx a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of CVRX is around 8.26 USD . This means that CVRX is currently overvalued and has a potential downside of -15.63%.
Is CVRX a buy, sell or hold?
- Strong Buy: 5
- Buy: 1
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the CVRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 10.8 | 10.6% |
| Analysts Target Price | 10.8 | 10.6% |
| ValueRay Target Price | 9.3 | -5.2% |
CVRX Fundamental Data Overview November 05, 2025
P/S = 4.9574
P/B = 3.5463
Beta = 1.221
Revenue TTM = 54.7m USD
EBIT TTM = -46.9m USD
EBITDA TTM = -46.2m USD
Long Term Debt = 49.4m USD (from longTermDebt, last quarter)
Short Term Debt = 333.0k USD (from shortTermDebt, last quarter)
Debt = 50.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -44.5m USD (from netDebt column, last quarter)
Enterprise Value = 226.5m USD (270.9m + Debt 50.5m - CCE 95.0m)
Interest Coverage Ratio = -8.67 (Ebit TTM -46.9m / Interest Expense TTM 5.41m)
FCF Yield = -17.41% (FCF TTM -39.4m / Enterprise Value 226.5m)
FCF Margin = -72.14% (FCF TTM -39.4m / Revenue TTM 54.7m)
Net Margin = -95.61% (Net Income TTM -52.3m / Revenue TTM 54.7m)
Gross Margin = 84.04% ((Revenue TTM 54.7m - Cost of Revenue TTM 8.72m) / Revenue TTM)
Gross Margin QoQ = 84.26% (prev 83.51%)
Tobins Q-Ratio = 1.89 (Enterprise Value 226.5m / Total Assets 119.6m)
Interest Expense / Debt = 2.91% (Interest Expense 1.47m / Debt 50.5m)
Taxrate = 0.02% (-3000 / -14.7m)
NOPAT = -46.9m (EBIT -46.9m * (1 - 0.02%)) [loss with tax shield]
Current Ratio = 11.99 (Total Current Assets 116.1m / Total Current Liabilities 9.69m)
Debt / Equity = 0.87 (Debt 50.5m / totalStockholderEquity, last quarter 57.9m)
Debt / EBITDA = 0.96 (negative EBITDA) (Net Debt -44.5m / EBITDA -46.2m)
Debt / FCF = 1.13 (negative FCF - burning cash) (Net Debt -44.5m / FCF TTM -39.4m)
Total Stockholder Equity = 65.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -43.70% (Net Income -52.3m / Total Assets 119.6m)
RoE = -79.31% (Net Income TTM -52.3m / Total Stockholder Equity 65.9m)
RoCE = -40.66% (EBIT -46.9m / Capital Employed (Equity 65.9m + L.T.Debt 49.4m))
RoIC = -40.69% (negative operating profit) (NOPAT -46.9m / Invested Capital 115.2m)
WACC = 9.32% (E(270.9m)/V(321.5m) * Re(10.51%) + D(50.5m)/V(321.5m) * Rd(2.91%) * (1-Tc(0.00)))
Discount Rate = 10.51% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.89%
Fair Price DCF = unknown (Cash Flow -39.4m)
EPS Correlation: 33.32 | EPS CAGR: 25.64% | SUE: 2.52 | # QB: 1
Revenue Correlation: 92.65 | Revenue CAGR: 33.13% | SUE: 0.79 | # QB: 0
Additional Sources for CVRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle